Latest Hotspot

HOOKIPA Pharma reveals FDA's approval for their new investigative drug, HB-500, to treat HIV

29 November 2023
3 min read

HOOKIPA Pharma Inc., a firm involved in the creation of a novel category of immunotherapeutics via its unique arenavirus platform, has officially disclosed that the FDA has given the clearance for its IND application for HB-500, This is a new arenaviral therapeutic vaccine designed for HIV treatment.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

HOOKIPA is tasked with propelling the HIV project towards completion with a Phase 1b clinical trial. Post this, Gilead gains exclusive jurisdiction to carry on with the program's development.

"We're proud to announce our fourth active IND project at HOOKIPA, attesting to the wide-ranging potential of our arenavirus platform-encompassing several diseases and indications." said Joern Aldag, HOOKIPA's Chief Executive Officer. "Devising a strong and extensive T cell reaction capable of eliminating infected cells is key to combating HIV. Our groundbreaking arenaviral therapeutic vaccine holds potential to tackle the prevalent gap for a functional HIV cure."

Nature Partner Journals Vaccines recently publicized the co-preclinical analysis by HOOKIPA and Gilead, which acted as groundwork for the IND submission. The examinations published involved a simian immunodeficiency virus model, frequently applied as an HIV surrogate in preclinical settings. The data revealed that:

The arenaviral therapeutic vaccination was well tolerated, generating vigorous, reliable and lasting immune reactions in non-human primates; also, The arenaviral therapeutic vaccination considerably mitigated the SIV viral load and clinical symptoms in these animals in comparison to a placebo.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, targets, organizations, clinical trials, clinical results, and drug patents related to this indication.

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 28, 2023, there are 1540 investigational drugs for HIV Infections, including 263 targets, 948 R&D institutions involved, with related clinical trials reaching 10549, and as many as 95449 patents.

HB-500 is an alternating, 2-vector arenaviral therapeutic vaccine for the treatment of HIV. One vector is based on lymphocytic choriomeningitis virus as its arenaviral backbone; another vector is based on Pichinde virus Both encode the same HIV antigens. The alternating 2-vector approach is designed to further focus the immune response against the target antigen. HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

图形用户界面, 文本, 应用程序

描述已自动生成

Unveiling the Secrets of JAK2 Inhibitors: Stay Updated with the Latest Advances?
Unveiling the Secrets of JAK2 Inhibitors: Stay Updated with the Latest Advances?
29 November 2023
JAK2 inhibitors: Revolutionizing treatments for hematological disorders with a promising future.
Read →
Sandoz introduces Hyrimoz® (adalimumab) high-dose variant in Europe to enhance patient treatment
Latest Hotspot
3 min read
Sandoz introduces Hyrimoz® (adalimumab) high-dose variant in Europe to enhance patient treatment
29 November 2023
Sandoz announces the launch of its citrate-free high concentration Hyrimoz® (adalimumab) in Europe, with availability starting today in various countries.
Read →
Decoding Axicabtagene Ciloleucel: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
Decoding Axicabtagene Ciloleucel: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
29 November 2023
On 11 Dec 2023, The clinical data about Axicabtagene Ciloleucel from pivotal ZUMA-7 study will be updated in 2023 ASH.
Read →
European Commission approves Ascendis Pharma's YORVIPATH® (palopegteriparatide) for treating chronic Hypoparathyroidism in adults
Latest Hotspot
3 min read
European Commission approves Ascendis Pharma's YORVIPATH® (palopegteriparatide) for treating chronic Hypoparathyroidism in adults
29 November 2023
European Commission gives the green light to Ascendis Pharma's YORVIPATH® (palopegteriparatide) for managing chronic Hypoparathyroidism in adults.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.